ArticleScientific reports2025
2D and 3D in vitro photodynamic activities of tetra-substituted symmetric water-soluble cationic zinc(II) phthalocyanines on cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Synthesis of thiol-functionalized metal phthalocyanines-silver nanoparticles assemblies and their photophysics.Scientific reports · 2026Article
- Ferroptosis with Contributions from Apoptosis and Necroptosis in Porphyrazine III-Based Photodynamic Therapy of Primary Human Gliomas.Pharmaceutics · 2026Article
- Aggregation Tendency, Cellular Uptake, and Viability Effects of Structurally Distinct Carbazole-Phthalocyanine Gold Nanoconjugates.ACS organic & inorganic Au · 2026Article
- pH-Responsive Isoprenoid-Antitumoral Polymer Conjugates for Superior Drug Loading via Self-Assembly and Endosomal-Targeted Anticancer Activity.ChemMedChem · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In this study, the PDT activities of 2,9(10),16(17),23(24)-tetrakis(2-dimethylammoniumethoxy) phthalocyaninatozinc(II) tetraiodide (ZnPc1) and 1,8(11),15(18),22(25)-tetrakis(2-trimethylaminoethoxy)phthalocyaninatozinc(II)tetraiodide (ZnPc2) compounds were investigated in 2D monolayer cultures and 3D spheroids of three human cancer cell lines: human submaxillary salivary gland epidermoid carcinoma (A253), human colon colorectal adenocarcinoma (HT29), and human pharynx squamous carcinoma (FaDu) cells. The results indicate that both molecules are non-toxic in the absence of light, which is a crucial feature of an effective photosensitizer. Upon exposure to light, ZnPc1 exhibited significant cytotoxicity in all three cell lines, particularly in FaDu cells, in both 2D monolayer cultures and 3D spheroids, whereas ZnPc2 showed moderate efficacy compared to ZnPc1. PDT using both phthalocyanine (Pc) molecules resulted in substantial reactive oxygen species (ROS) production. Delayed ROS production is higher than that of immediate ROS, indicating their ability to stimulate ROS production over an extended period and retain an oxidative stress response in the cells rather than immediately after PDT. Among these molecules, ZnPc1 induced both immediate and delayed ROS production more efficiently than ZnPc2. Furthermore, singlet oxygen yields of ZnPc1 were higher than ZnPc2, which is consistent with the cytotoxicity results. These findings confirmed that PDT induces an ROS-mediated cytotoxic response. The mechanisms of cellular death triggered by PDT were evaluated, and the results revealed that apoptosis was the predominant process. These findings underscore the potential of ZnPc1 as a potent photosensitizer in PDT while also highlighting the differences between 2D and 3D culture models in evaluating PDT efficacy. While the 2D system enables simplified cytotoxicity evaluation, the 3D spheroid model better replicates physiologically relevant environment and treatment resistance. This comparison underscores necessity of integrating 3D models in PDT studies for more predictive in vivo insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.